Onxeo has engaged MCT (Regional CRO specialized on Middle East and Africa) to expand “Relieve” phase III HCC study in 3 Middle East countries (Lebanon, Egypt and Saudi Arabia). More information in Onxeo press release: 150326EN_Livatag
Related Posts
Pediatric Gastroenterology Study The Gambia, Farafenni Site
News / June 18, 2021
Meet our team in The Gambia
News / January 26, 2022